Skip to main content
OpenTrials
Completed

NCT Number: NCT01942408

The Effect of Early Repeat Atrial Fibrillation (AF) Ablation on AF Recurrence

Atrial fibrillation (AF) is the commonest condition affecting the rhythm of the heart and causes an irregular and often rapid heartbeat. Developing this condition may cause significant health problems and symptoms that affect normal day-to-day activities. Patients with AF also have a shorter life expectancy on average. Tablets used to try to normalise the heart rhythm rarely work well. As a result, doctors have devised a treatment to try to cure this condition. Special wires (called catheters) are used to deliver heat energy (called ablation) on the inside surface of the heart. This technique has been used more and more in recent years for patients with troublesome symptoms due to AF.

The aim of the treatment is to draw lines of ablation in specific places in the heart. Unfortunately, a lot of patients (almost 50%) get AF again after this treatment and most of these patients have a second treatment performed. It is usually found at this second treatment that gaps have developed in the lines of ablation that were drawn the first time around. The investigators think that electively doing a second treatment to close these gaps a couple of months after the first treatment may mean that fewer of these patients will get AF again in the future. The investigators also want to find out what factors make a line of ablation less likely to develop gaps.

In this study, participants will be assigned to one of two groups:

1. a "standard care" group, who will have a single treatment initially. 2. a "repeat study" group, who will have the initial treatment followed by a second treatment 8-10 weeks later.

For patients in the "repeat study group", investigators will see how many have developed gaps since their first treatment. The investigators will look at where these gaps are and will compare this with information collected during the first treatment to try to work out why the gap has developed. Any gaps found at the second treatment will be closed again.

All participants will then be monitored carefully over 12 months to see how many from each group get AF again. To do this, all participants will be given a handheld heart rhythm monitor to keep until the end of the study. This device is simple to use. Participants will be asked to make a 30 second recording of their heart rhythm each day and also whenever they have symptoms. These recordings will be downloaded at review appointments arranged 6 weeks, 3 months, 6 months and 12 months after the initial ablation procedure.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Liverpool Heart and Chest Hospital

Liverpool, Merseyside, L14 3PE, United Kingdom

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged over 18 years
  • Current pattern of paroxysmal AF (defined as electrocardiogram (ECG)-proven episodes of AF which are self-limiting and last less than 7 days on each occasion, or which were cardioverted electrically or pharmacologically less than 48 hours from onset)
  • Due to undergo pulmonary vein isolation by radiofrequency (RF) ablation

Exclusion criteria

  • Inability or unwillingness to receive oral anticoagulation with warfarin or alternative anticoagulant drug
  • Previous ablation procedure for AF
  • Unwillingness or inability to complete the required follow-up arrangements
  • Current pattern of persistent (episodes of AF which last longer than 7 days or which last longer than 48 hours but require electrical or pharmacological cardioversion) or permanent AF
  • Prior prosthetic mitral valve replacement or severe structural cardiac abnormality
  • Reversible cause for AF
  • Known infiltrative cardiomyopathy
  • Known severe left ventricular systolic function (ejection fraction <35%)
  • Pregnancy

Treatment and study plan

Repeat PVI

Procedure

Repeat EP study 8-10 weeks post-initial PVI with re-isolation of PV reconnection

Primary outcomes

  1. Atrial tachyarrhythmia (AT) recurrence

    Time frame: 12 months post-initial pulmonary vein isolation (PVI)

    The proportion of patients maintaining freedom from AT for 12 months post-initial PVI (after an initial 12 week blanking period)

Secondary outcomes

  1. Quality of life measures

    Time frame: 12 months post-initial PVI

    Quality of life 12 months after initial ablation, as quantified by the validated Atrial Fibrillation Effect on Quality of Life (AFEQT) questionnaire.

  2. Time to recurrence

    Time frame: 12 months post-initial PVI

    Time to first AT recurrence after the initial blanking period

  3. Comparison of major complication rates

    Time frame: 4 months post-initial PVI

    Comparison of major complication rates (occurring within 30 days after a PVI procedure), to include cardiac tamponade, stroke/transient ischemic attack (TIA), myocardial infarction, pulmonary vein stenosis, phrenic nerve paralysis, oesophageal perforation/atrio-oesophageal fistula, major vascular complications and death

Other outcomes

  1. Pulmonary vein (PV) reconnection in patients with and without early recurrence

    Time frame: 3 months post-initial PVI

    Comparison of prevalence, distribution and location of sites of late PV reconnection (8-10 weeks after their initial PVI) between patients with and without early recurrence in the "repeat study" group

  2. Correlation between Visitag data and sites of PV reconnection

    Time frame: 4 months post-inital PVI

    Correlation between initial Force-Time-Power Integral (as assessed using Visitag™) and a) sites of acute PV reconnection (including those unmasked by adenosine), and b) late PV reconnection (8-10 weeks after their initial PVI)

Sponsors and collaborators

Lead sponsor

Liverpool Heart and Chest Hospital NHS Foundation Trust

Other

Collaborators

  • Biosense Webster, Inc.

Registry information

Official study title

Pulmonary Vein Re-isolation as a Routine Strategy: a Success Rate Evaluation

Acronym: PRESSURE

Important dates

Study start
2013
Primary completion
2016
Study completion
2016
First posted
Sep 16, 2013
Registry last updated
Mar 3, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.